BRPI0520686A2 - uso de agentes modificantes de transcriptoma associado a quimioterapia ou radioterapia contra o cáncer - Google Patents

uso de agentes modificantes de transcriptoma associado a quimioterapia ou radioterapia contra o cáncer

Info

Publication number
BRPI0520686A2
BRPI0520686A2 BRPI0520686-3A BRPI0520686A BRPI0520686A2 BR PI0520686 A2 BRPI0520686 A2 BR PI0520686A2 BR PI0520686 A BRPI0520686 A BR PI0520686A BR PI0520686 A2 BRPI0520686 A2 BR PI0520686A2
Authority
BR
Brazil
Prior art keywords
transcriptome
radiotherapy
modifying agents
chemotherapy
agents associated
Prior art date
Application number
BRPI0520686-3A
Other languages
English (en)
Inventor
Alfonso Duenas Gonzalez
Luis Estrada Flores
Original Assignee
Univ Mexico Nacional Autonoma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Mexico Nacional Autonoma filed Critical Univ Mexico Nacional Autonoma
Publication of BRPI0520686A2 publication Critical patent/BRPI0520686A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

USO DE AGENTES MODIFICANTES DE TRANSCRIPTOMA ASSOCIADO A QUIMIOTERAPIA OU RADIOTERAPIA CONTRA O CáNCER. A presente invenção se relaciona com o uso de agentes modificantes do transcriptoma com o objetivo de impedir as células malignas de realizar as alterações gênicas necessárias para desenvolver dano celular e sobreviver a quimioterapia ou radioterapia. Esta combinação de modificantes do transcriptoma serão agentes que inibem a maquinaria de metilação do DNA associado a uma substância que impessa as modificações pós-traducionais das histonas. Se apresenta um kit de tratamento que consiste na administração de uma dose efetiva de hidralazina associado a vaíproato de magnésio para coadjuvar com a radioterapia ou quimioterapia no tratamento de pacientes com câncer.
BRPI0520686-3A 2005-11-16 2005-11-16 uso de agentes modificantes de transcriptoma associado a quimioterapia ou radioterapia contra o cáncer BRPI0520686A2 (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/MX2005/000106 WO2007075077A1 (es) 2005-11-16 2005-11-16 Uso de agentes modificantes del transcriptoma más quimioterapia o radioterapia contra el cáncer

Publications (1)

Publication Number Publication Date
BRPI0520686A2 true BRPI0520686A2 (pt) 2009-05-19

Family

ID=38218257

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0520686-3A BRPI0520686A2 (pt) 2005-11-16 2005-11-16 uso de agentes modificantes de transcriptoma associado a quimioterapia ou radioterapia contra o cáncer

Country Status (12)

Country Link
US (1) US9186339B2 (pt)
EP (1) EP1949898A1 (pt)
JP (1) JP2009519898A (pt)
CN (1) CN101355934A (pt)
AR (1) AR058192A1 (pt)
AU (1) AU2005339587B2 (pt)
BR (1) BRPI0520686A2 (pt)
CA (1) CA2630334C (pt)
CR (1) CR9979A (pt)
PE (1) PE20070722A1 (pt)
UY (1) UY29901A1 (pt)
WO (1) WO2007075077A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8491927B2 (en) 2009-12-02 2013-07-23 Nimble Epitech, Llc Pharmaceutical composition containing a hypomethylating agent and a histone deacetylase inhibitor
US20130102556A1 (en) * 2010-02-02 2013-04-25 The Johns Hopkins University Use of N1,N4-bis[3-(Ethylamino)Propyl]-2-Butene-1,4-Diamine Compounds in Combination with Epigenetic-Acting Pharmaceuticals for Enhanced Cancer Therapy
HK1251862A1 (zh) * 2014-12-02 2019-04-26 普拉斯派克特查特凯尔Rwmc有限责任公司 治疗癌症的方法和组合物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6300373B1 (en) * 1993-09-10 2001-10-09 American Biogenetic Sciences, Inc. Antiproliferative and neurotrophic molecules
US6713043B2 (en) * 1996-02-29 2004-03-30 The Trustees Of Columbia University In The City Of New York Antimicrobial activity of gemfibrozil
EP1293205A1 (en) * 2001-09-18 2003-03-19 G2M Cancer Drugs AG Valproic acid and derivatives thereof for the combination therapy of human cancers, for the treatment of tumour metastasis and minimal residual disease
JP2005536509A (ja) * 2002-07-11 2005-12-02 コンビナトアールエックス インコーポレーティッド 新生物の治療のための薬物の組み合わせ
AU2003288263A1 (en) * 2002-10-16 2004-05-04 Pharmacia Italia S.P.A. Use of substituted acrylolyl distamycin derivatives in combination with demethylating agents, in the treatment of cancer
US20050037992A1 (en) * 2003-07-22 2005-02-17 John Lyons Composition and method for treating neurological disorders
US20050100529A1 (en) * 2003-11-06 2005-05-12 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders
DE602004014723D1 (de) * 2004-04-30 2008-08-14 Desitin Arzneimittel Gmbh Histondeacetylase-Inhibitor enthaltende Formulierung zur zweiphasigen Freisetzung

Also Published As

Publication number Publication date
PE20070722A1 (es) 2007-09-28
US9186339B2 (en) 2015-11-17
WO2007075077A8 (es) 2008-11-20
CA2630334A1 (en) 2007-07-05
AU2005339587A1 (en) 2007-07-05
AU2005339587B2 (en) 2011-11-03
WO2007075077A1 (es) 2007-07-05
CA2630334C (en) 2013-07-23
AR058192A1 (es) 2008-01-23
UY29901A1 (es) 2007-04-30
AU2005339587A8 (en) 2008-07-24
US20090196851A1 (en) 2009-08-06
CN101355934A (zh) 2009-01-28
CR9979A (es) 2009-08-24
EP1949898A1 (en) 2008-07-30
JP2009519898A (ja) 2009-05-21

Similar Documents

Publication Publication Date Title
BRPI0507039A8 (pt) composição, métodos de tratar um paciente com câncer, e de inibir a angiogênese em um tumor, e, kit
BR112020017090A8 (pt) Imunoterapias relacionadas com microbioma
BR112015008255A2 (pt) método para o diagnóstico, prognóstico e tratamento de metástase de câncer de próstata
BR112014030750A2 (pt) Método para diagnóstico, prognóstico e tratamento da metástase do câncer pulmonar
Zhou et al. PIWI-interacting RNAs: critical roles and therapeutic targets in cancer
BRPI0607809A2 (pt) uso de uma composição compreendendo nanopartìculas, composição e kit
BR112013002298A2 (pt) complexação de ácidos nucleicos com componentes catiônicos reticulados com dissulfeto para transfecção e estimulação imunológica.
BRPI0810384B8 (pt) terapia enzimática anticâncer
BR112015033053A2 (pt) método de tratamento de câncer em um sujeito, método de estimulação do sistema imune em um sujeito, método de aumentar a distribuição de um agente anticâncer a uma célula tumoral, composição, e kit
Braicu et al. Altered expression of miR-181 affects cell fate and targets drug resistance-related mechanisms
BR112012014569A8 (pt) métodos e composições para destruição de tumores
GT201200275A (es) Proteína de fusión robo1-fc y su utilización en el tratamiento de tumores
WO2005116259A3 (en) Use of gene expression profiling to predict survival in cancer patient
BRPI0719093B8 (pt) sistema transdérmico terapêutico com micro reservatórios de pares de ions
Duan et al. MicroRNA-145: a promising biomarker for hepatocellular carcinoma (HCC)
IL191797A0 (en) Combination of azd2171 and pemetrexed
WO2006133361A3 (en) Use of gene expression profiling to predict survival in cancer patient
MX2020013883A (es) Tratamientos oncológicos con agentes de zinc.
IL284854A (en) Methods for labeling eukaryotic cells from a multicellular organism as well as for treating and/or diagnosing a cancer using modified monosaccharide compounds
BR112012027463A2 (pt) método terapêutico, composição farmacêutica, uso de tri-iodotironina (t3) ou de análogo bioquímico da mesma, tri-iodotironina (t3) ou um análogo bioquímico da mesma, e, kit
CO2023016058A2 (es) Agentes de rnai para inhibir la expresión de mucina 5ac (muc5ac), composiciones de estos y métodos de uso
UY29901A1 (es) Uso de agentes modificantes del transcriptoma mas quimioterapia o radioterapia contra el cancer
PT1653964E (pt) Terapia de combinação para o cancro compreendendo azd2171 e zd1839
ECSP088454A (es) Uso de agentes modificantes del transcriptoma más quimioterapia o radioterapia contra el cáncer
BRPI0608043A2 (pt) composição, método que promove a regressão do tumor, linhagem celular, método de identificação de um agente quimioterapêutico, método que promove a apoptose em células do tumor de mama, método de identificação de um agente que aumenta a apoptose em uma célula, uso de um agente e uso do ácido d-ala-l-glu-diaminopimélico

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL